Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Thomas Bertsch currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, KATAKAM, SUDHAKAR, in 1 distinct art unit. KATAKAM, SUDHAKAR is the busiest examiner for the portfolio, managing the 1 busiest examiner pending action. This structure shows a very specific and limited prosecution footprint at the present time.
The concentration of the 1 pending office action under 1 distinct examiner allows for a direct and consistent dialogue with the USPTO. Since KATAKAM, SUDHAKAR is the only examiner involved, the applicant can focus on addressing his specific technical concerns. This 1 busiest examiner pending status in 1 distinct art unit reduces the administrative complexity of the portfolio. Practitioners can leverage this focus to develop a deep understanding of the examiner's perspective on the 1 pending office action within the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17778396 | OLIGOPEPTIDE THAT INHIBITS ANGIOGENESIS AND VASCULAR FUNCTION | KATAKAM, SUDHAKAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17778396 | OLIGOPEPTIDE THAT INHIBITS ANGIOGENESIS AND VASCULAR FUNCTION | KATAKAM, SUDHAKAR | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17778396 | OLIGOPEPTIDE THAT INHIBITS ANGIOGENESIS AND VASCULAR FUNCTION | KATAKAM, SUDHAKAR | 1658 | §101§102 | Non-Final OA | — | Pending | May 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThomas Bertsch has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sudhakar Katakam has the most, with 1 of Thomas Bertsch's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
